74
Participants
Start Date
December 9, 2014
Primary Completion Date
September 24, 2016
Study Completion Date
October 1, 2017
Nab-Paclitaxel and Gemcitabine
Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
Medical University of Vienna, Vienna
Mount Sinai Hospital, New York
Montefiore Medical Center, The Bronx
University of Rochester Medical Center, Rochester
University of Pennsylvania, Abramson Cancer Center, Philadelphia
University of Pennsylvania; Abramson Cancer Center at Presbyterian Medical Center, Philadelphia
Fox Chase Cancer Center, Philadelphia
Vanderbilt University/Ingram Cancer Center, Nashville
University of Tennessee Medical Center, Knoxville
University of Michigan Health System, Ann Arbor
University of Michigan Medical Center, Ann Arbor
Siouxland Hematology-Oncology Associates, Sioux City
Aurora Cancer Care, Wauwatosa
University of Wisconsin-Madison, Madison
Gundersen Health System, La Crosse
Metro Minnesota CCOP, Saint Louis Park
Advocate Christ Medical Center, Oak Lawn
Northwestern University, Chicago
Ochsner Medical Center, New Orleans
University of Texas Southwestern Medical Center, Dallas
Colorado Cancer Research Program, Denver
Tufts Medical Center, Boston
University Massachusetts Memorial Medical Center, Worcester
St. Joseph Mercy Health System, Ann Arbor
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Celgene Corporation
INDUSTRY
PrECOG, LLC.
OTHER